He Liu: The Shift in China’s Medtech Sector is Truly a Game-Changer
He Liu, Chief Executive Officer at IMPELINNO GmbH, reposted from China Medtech Radar on LinkedIn:
”The shift in China’s Medtech sector is truly a game-changer, and our latest intelligence report, “The Surgeon-Engineered Solution,” captures the pivot point.
We are witnessing a fundamental move from being a cost-driven “Manufacturing” hub to a high-value “Intelligent Manufacturing” powerhouse, driven by the Med-Eng Integration model.
This means Chinese urgeons are now the primary nnovators, using their deep clinical insights to architect superior, clinical-driven devices like the ValveClamp® for TEER, MissilEX® thrombectomy and beyond, which exemplify the competitive landscape in China’s Medtech Innovation ecosystem.
I invite you to read the full analysis and engage with us: How can we best collaborate to plug into this high-velocity ecosystem? Let’s drive the future of MedTech together.”
Quoting China Medtech Radar‘s post:
”China’s medtech innovation model is undergoing a seismic shift!
The evolution of China’s medtech innovation from a cost-driven model to a clinical-led ecosystem warrants strategic consideration from the global medtech community.
We are excited to share our latest intelligence report, “The Surgeon-Engineered Solution,” which provides unique insight into the driving force behind China’s move from “Manufacturing” to “Intelligent Manufacturing.”
Key Takeaways for Global Stakeholders:
- The Surgeon as the Innovator: Chinese physicians are no longer just users; they are the source of medtech innovation. Their deep, clinical insights into unmet clinical needs are defining product development from the ground up, creating “China Solutions” to real-world problems.
- Med-Eng Integration: This is a highly efficient “Clinical-Engineering-Industry-Policy” ecosystem. It means surgeons and engineers collaborate from Day One to solve clinical pain points, leading to rapid RandD and shorter time-to-market.
- From Manufacturing to IntelligentManufacturing: This is the shift from a cost-focused, often imitative production model to a high-value, data-driven system utilizing AI and robotics to achieve breakthroughs in precision and quality.
- Real-World Success: Learn how this model has led to breakthroughs in China’s medtech like the Valve Clamp, Mitral Clip System (democratizing advanced repair), the MissilEX Intracranial Thrombectomy Device (demonstrating superior first-pass recanalization rates) and the Orthopedic Surgical Robot.
The competitive landscape in China’s medtch is being redefined.
For global medtech stakeholders, understanding this clinically-driven model is critical for successful internationalcollaboration and marketstrategy.
We invite you to read our exclusive analysis and join the conversation on fostering a collaborative future for medtechinnovation between China and the world.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?
-
Feb 28, 2026, 16:38Akinchan Bhardwaj: Targeting SBK2 for Selective Inflammasome Resolution in Atherosclerosis